Skip to search formSkip to main contentSkip to account menu

ONO-5334

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Thiazolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys
This study evaluated the long-term effects of the cathepsin K inhibitor ONO-5334 on bone mass and strength in ovariectomised (OVX… 
2015
2015
An oral cathepsin K inhibitor ONO-5334 inhibits N-terminal and C-terminal collagen crosslinks in serum and urine at similar plasma concentrations in postmenopausal women.
Review
2015
Review
2015
Cathepsin K inhibitors: emerging treatment options for osteoporosis
Cathepsin K inhibitors: emerging treatment options for osteoporosis 47 1 3 Cathepsin K belongs to the group of cysteine proteases… 
2014
2014
Modeling and simulation of bone mineral density response from a phase 2 study of ONO‐5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis
ONO‐5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. The objectives of this modeling… 
2014
2014
Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns
The purpose of the study was clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers using sustained… 
2013
2013
Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women
A sustained-release tablet (SRT) of ONO-5334 was compared to the immediate-release tablet (IRT) dose, which demonstrated effects… 
Review
2011
Review
2011
[New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334].
ONO-5334, an orally-administered low-molecular compound, is a selective synthetic inhibitor of cathepsin K which is specifically… 
2010
2010
Gateways to clinical trials.
Aclidinium bromide, AE-37, Alemtuzumab, AMA1-C1/ISA 720, Amlodipine besylate/atorvastatin calcium, Arachidonic acid, Arbaclofen… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)